Clinical Trial Update: Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating erlotinib and docetaxel with concomitant boost radiation therapy for head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED